Evolus Inc (EOLS) Inventory Turnover Ratio, from third quarter 2026 to third quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 
Evolus Inc   (NASDAQ: EOLS)
 

Evolus Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Due to inventory build up in the third quarter 2026, Evolus Inc 's inventory turnover ratio sequentially decreased to 2.51 in the third quarter 2026, unsurprisingly, as the Evolus Inc markets continue to deteriorate, and EOLS's faces growing challenges to bring down its inventories. Evolus Inc 's average inventory processing period in the Sep 30 2026 quarter, has increased to 145 days, from 108 days, in the Jun 30 2026 quarter.

Within Healthcare sector 112 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 744 in the second quarter 2026, to 1057.

EOLS Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Evolus Inc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EOLS Inventory Turnover Ratio (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Inventory Growth 151.91 % 54.58 % 147.32 % 121.77 % 120.73 %
Y / Y Cost of Sales Growth 18.55 % 12.1 % 14.29 % 11.88 % 21.14 %
Inventory Turnover Ratio (TTM) 2.51 3.37 3.71 4.15 4.74
EOLS's Total Ranking # 1057 # 744 # 713 # 655 #
Average inventory processing period 145 108 98 88 77
Seq. Inventory Growth 102.47 % 64.93 % -8.04 % -17.97 % 24.24 %
Seq. Cost of Sales Growth 1.35 % 12.1 % -25 % 39.13 % -4.17 %




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 25
Healthcare Sector # 113
Overall Market # 1057

Inventory Turnover Ratio Statistics
High Average Low
16.55 5.36 1.05
(Mar 31 2022)   (Dec 31 2019)



EOLS Company Profile >> Back to EOLS Efficiency Comparisons >> Compare EOLS Inventory Turnover Ratio to its Competitors

Financial Statements
Evolus Inc 's Inventories $ 83 Millions Visit EOLS's Balance sheet
Evolus Inc 's Cost of Revenues TTM $ 110 Millions Visit EOLS's Income Statement
What are EOLS's Sales? Visit EOLS's Sales by Segment

Other Inventory Turnover Ratios
Evolus Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
EOLS's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for EOLS's Competitors
Inventory Turnover Ratio for EOLS's Suppliers
Inventory Turnover Ratio for EOLS's Customers

You may also want to know
EOLS's Sales Growth Rates EOLS's Pe Price to earnings ratio EOLS's Receivables Turnover Ratio EOLS's Stock Quote
EOLS's Net Income Growth Rates EOLS's Ps Price to Sales ratio EOLS's Sales per Employee EOLS's Asset Turnover Ratio
EOLS's Net Margin EOLS's Pb Price to Book ratio EOLS's Financial Strength Ratios EOLS's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Sep 30 2026 Inventories at quarter ending Sep 30 2026
Baxter International Inc   3.57 $ 8,117.000  Millions$ 2,277  Millions
Bausch Health Companies Inc   3.54 $ 4,518.000  Millions$ 1,276  Millions
Exelixis Inc   3.49 $ 93.324  Millions$ 27  Millions
Abbvie Inc   3.40 $ 17,346.000  Millions$ 5,108  Millions
Gilead Sciences Inc   3.30 $ 6,219.000  Millions$ 1,884  Millions
Teva Pharmaceutical Industries Limited  3.16 $ 8,011.000  Millions$ 2,537  Millions
Msa Safety Inc  3.00 $ 1,063.235  Millions$ 354  Millions
Mimedx Group Inc   2.98 $ 70.562  Millions$ 24  Millions
Ligand Pharmaceuticals Incorporated  2.93 $ 34.495  Millions$ 12  Millions
Neogen Corporation  2.89 $ 464.774  Millions$ 161  Millions
Zevra Therapeutics Inc   2.82 $ 6.736  Millions$ 2  Millions
Biomerica Inc   2.65 $ 4.297  Millions$ 2  Millions
Dexcom Inc   2.65 $ 1,867.500  Millions$ 705  Millions
Angiodynamics Inc   2.50 $ 142.709  Millions$ 57  Millions
Pro dex Inc   2.45 $ 53.753  Millions$ 22  Millions
Illumina Inc   2.36 $ 1,458.000  Millions$ 618  Millions
Mirum Pharmaceuticals Inc   2.35 $ 59.684  Millions$ 25  Millions
Aquestive Therapeutics Inc   2.34 $ 16.928  Millions$ 7  Millions
Resmed Inc   2.33 $ 2,214.675  Millions$ 952  Millions
Beta Bionics Inc   2.31 $ 53.285  Millions$ 23  Millions
Merit Medical Systems Inc  2.25 $ 817.001  Millions$ 363  Millions
Bioventus Inc   2.24 $ 183.856  Millions$ 82  Millions
Johnson and Johnson  2.17 $ 32,222.000  Millions$ 14,824  Millions
Standard Biotools Inc   2.16 $ 39.539  Millions$ 18  Millions
Glaukos Corp  2.13 $ 131.180  Millions$ 62  Millions
Organon and Co   2.08 $ 2,859.000  Millions$ 1,371  Millions
Repligen Corp  2.07 $ 372.472  Millions$ 180  Millions
Boston Scientific Corporation  2.06 $ 6,502.000  Millions$ 3,153  Millions
Bausch and Lomb Corp  2.01 $ 1,986.000  Millions$ 990  Millions
Clearpoint Neuro Inc   1.98 $ 17.564  Millions$ 9  Millions

Date modified: 2026-11-05T06:09:11+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.